Generics market failings cost Mexico $144 million annually, says report

16 August 2017
drugs_pills_tablets_big

At two years after the entry of the first copycat product, the penetration of generic drugs reaches 21.4% of the market in Mexico, where in the USA it climbs to 89% and in Canada it is 74%.

That is one of a series of findings from a report that show just how bad the market is for drugs with expired patents in Mexico, and how it is failing the country’s people.

"In Mexico, it takes, on average, more than two years between the expiration of a patent and the launch of the first generic, while in the USA, the generic is introduced almost immediately"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics